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Abstract 22 
It is widely accepted that the c-Fos gene has a role in proliferation and differentiation of 23 
bone cells. ATP-induced c-Fos activation is relevant to bone homeostasis, because nucleotides 24 
that are present in the environment of bone cells can contribute to autocrine/paracrine signalling. 25 
Gut hormones have previously been shown to have an effect on bone metabolism. In this study 26 
we used the osteoblastic Saos-2 cell line transfected with a c-Fos-driven reporter stimulated with 27 
five gut hormones: glucose inhibitory peptide (GIP), glucagon-like peptide-1 (GLP-1), glucagon-28 
like peptide-2 (GLP-2), ghrelin, and obestatin, in the presence or absence of ATP. In addition, 29 
TE-85 cells were used to determine the time course of c-Fos transcript induction following 30 
stimulation with GLP-1, and GLP-2 with or without ATP, using reverse transcription qPCR.  31 
The significant results from the experiments are as follows: higher level of c-Fos 32 
induction in presence of GIP, Obestatin (p=0.019 and p=0.011 respectively), and GIP combined 33 
with ATP (p<0.001) using the luciferase assay; GLP-1 and GLP-2 combined with ATP (p=0.034 34 
and p=0.002, respectively) and GLP-2 alone (p<0.001) using qPCR. 35 
In conclusion, three of the gut peptides induced c-Fos, providing a potential  mechanism 36 
underlying the actions of these hormones in bone which can be directed or enhanced by the 37 
presence of ATP.   38 
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Introduction 48 
Several studies have reported that c-Fos has a role in proliferation and differentiation of 49 
bone cells [1, 2]. ATP released from osteoblasts may activate P2 receptors on osteoclasts and/or 50 
other lining osteoblasts and could be a mechanism by which these cells establish cross talk for 51 
the control of bone remodelling, in addition to other paracrine factors as well as a direct cell-to-52 
cell contact [3]. 53 
The rationale for the experiments described in this paper is based on the actions of gut 54 
hormones as systemic regulators and their reported direct effects on bone cells [4, 5]. Animal 55 
models [6], and clinical trials [7–11]  have mainly shown an increase in the markers for bone 56 
formation. On the other hand, to our knowledge there are no reports focused on the measurement 57 
of c-Fos induction elicited by gut hormones and ATP in osteoblastic cells, however there is 58 
evidence that these regulators are able to activate the transcription of c-Fos. In this regard, GIP 59 
and GLP-1 have been shown to induce c-Fos transcriptional activation in the presence of 60 
glucose, showing a synergistic pattern, when they were added to pancreatic beta-cell cultures 61 
[12]. Also, GIP combined with Xenin-25, caused a significant increase in the number of c-Fos 62 
positive cells in the arcuate nucleus of a knockout mice model (lacking GIP-producing K cells) 63 
[13].  Another report showed that administration of low dose GLP-1 combined with  glucagon 64 
inhibited food intake induced c-Fos expression in the area postrema and amygdala [14]. 65 
Moreover, the effect of GLP-2 on c-Fos has been studied in primary rat astroglial cell cultures 66 
[15], and it has been demonstrated that GLP-2 has a role in hypertension regulation evaluated by 67 
c-Fos induction [16, 17]. Ghrelin (GHR) and obestatin (OB) can also modulate c-Fos expression, 68 
GHR  at neuronal level and so alter feeding patterns in rats  and OB) in  mouse embryonic 69 
fibroblast and adipose-like cells.[18, 19].  70 
We aimed to investigate whether or not the aforementioned five gut hormones were able 71 
to induce c-Fos in presence or absence of ATP in two osteoblastic cell lines: in Saos-2 using a 72 
luciferase assay and in TE-85, using a real time PCR assay, .  73 
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 74 
Methods 75 
Luciferase assay 76 
This assay was used to test the effects of GIP, GHR and OB, on  Saos-2 cells since these 77 
have been  demonstrated to express reliable levels of the receptors for those gut peptides [5]. 78 
Briefly, the Saos-2 cells had been   previously transfected with the c-Fos-luciferase reporter 79 
gene, in which the full c-Fos promoter spanning position -711 to -1 was linked to the firefly 80 
luciferase as the reporter gene, [20].  Transfected Saos-2 cells were stored in liquid nitrogen until 81 
needed. They were defrosted and expanded in culture medium ([DMEM], Invitrogen, Paisley, 82 
UK) containing a selective agent (Geneticin®, Sigma, Gillingham, UK) to favour the growth of 83 
transfected cells over the wild type. Then, cells were passaged to 96-well plates (white walls) 84 
and settled for 24 h, serum deprived for 24 h, and induced for 4 hours with gut peptides in 85 
presence or absence of ATP, diluted in DMEM serum free. Then, attached cells were washed in 86 
PBS, lysed and kept stored in -80oC. After 24 h, cells were defrosted at room temperature, and 87 
the assay was performed as follows: 100μL of luciferase reagent (Promega, Southampton, UK) 88 
was added to each well, and the chemiluminescence was measured every 10msec, for 10 sec in 89 
an Anthos luminometer microplate reader (Anthos Labtech Instruments, Salzburg, Austria). Two 90 
working concentrations of gut hormones were used: 10-9 and 10-8 M; ATP was used at 10-5M; 91 
PTH 10-9M was used as a positive control. Comparisons were performed per treatment against its 92 
paired control (i.e. DMEM with and without ATP, no added gut peptides). Experiments were 93 
repeated twice using ten replicates each time. The cell line Saos-2 was part of the cell bank  in 94 
Human Anatomy and Cell Biology Department, University of Liverpool, and its osteoblastic 95 
lineage has been tested previously using mRNA expression of bone markers [5]. 96 
RT-qPCR 97 
This procedure was performed on TE-85 cells, and the peptides under scrutiny were 98 
GLP-1 and GLP-2, since TE 85 cells have been shown to respond to these hormones. [5]. 99 
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Briefly, cells were passaged into 6-well plates, seeded and grown until confluence and serum 100 
deprived for 24 h. After that time, cells were washed in PBS and treated with the gut peptides 101 
with or without ATP 10-5M for 15, 30, 60 and 120 min. Then, cells were lysed with Tri 102 
Reagent®-chloroform (Invitrogen, UK), RNA was extracted and reverse transcribed. cDNA was 103 
analyzed for c-Fos level of expression, using beta-actin as reference gene.  104 
The gut peptides were used at a concentration of 10-8M and ATP was added at a final 105 
concentration of 10-5M. DMEM plus ATP (D+A), 10% Fetal calf serum DMEM (D+S) and PTH 106 
10-9M were used as positive controls. The low induction control (LIC) was DMEM without 107 
peptides or ATP. The results were normalized to fold change, using DMEM without ATP and 108 
are expressed as the average of fold change of 5-6 replicates in the iCycler iQ instrument (Bio-109 
Rad, Hertfordshire, UK). The cell line TE-85 was part of the cell bank  in Human Anatomy and 110 
Cell Biology Department, University of Liverpool, its osteoblastic features have  been tested 111 
previously using mRNA expression of bone markers [5]. 112 
Statistical analysis 113 
The comparisons were analyzed with SPSS software, using ANOVA with Bonferroni 114 
post hoc testing or unpaired t-tests to compare the means of the tests obtained between groups. 115 
The equality of variances in different samples was assessed using the test of Levene. The 116 
significance was set at p values less than 0.05. Results are presented as fold change ± standard 117 
error of the mean (SEM). 118 
Results 119 
Luciferase assay: induction of c-Fos in Saos-2 osteoblastic cell line 120 
c-Fos expression was higher with  GIP 10-8M treatment either in presence or absence of 121 
ATP (p=0.019 and p<0.001, respectively) when compared to respective controls (Fig. 1A). In the 122 
cases of GLP-1, GLP-2 and GHR treatments, no differences were observed in any experiment. 123 
OB only displayed a significant increase when a 10-8M treatment was present in the culture 124 
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medium (p=0.011), but the addition of ATP did not cause any significant change in the activation 125 
of c-Fos (Fig. 1B). 126 
RT-qPCR: time course of c-Fos expression in TE-85 osteoblastic cell line  127 
The effect of GLP-1 and GLP-2 was tested in TE-85, a cell line with a consistent 128 
expression pattern for those receptors. The results for all the positive controls (D+A, D+S and 129 
PTH) were consistently higher than the LIC at different point times (FIG 2A), and each of them 130 
showed different patterns of expression.   131 
Next, the analysis of the patterns after the induction with gut peptides (no ATP added), 132 
showed that treatment with GLP-1 prompted the highest expression of c-Fos at 60 min of 133 
exposure, with depletion at 120 min, this was similar to LIC. GLP-2 treatment also increased the 134 
induction of c-Fos at 60 min and was sustained up to 120 min, with a significant difference in 135 
relation to LIC (p<0.001) (Fig. 2B). The observations of peptide treatments combined with ATP, 136 
showed that the combination of GLP-1 plus ATP, increased c-Fos induction from 30 min, but a 137 
significant difference was observed at its highest peak at 60 min (p=0.021), with depletion at 120 138 
min. In the case of GLP-2 combined with ATP, the pattern of expression showed a significant 139 
increase at 30 min when compared against the control (D+A) (p=0.002), and also a significant 140 
difference was observed when compared to GLP-1 combined with ATP at 30 min (p=0.034) 141 
(Fig. 2C). To sum up , the induction of c-Fos caused by GLPs with added ATP, followed similar 142 
patterns to  those for the well-known inductors of c-Fos (D+A, D+S, PTH).   143 
 144 
Discussion 145 
Bone turnover has been described as a process in which localized parts of the skeleton are 146 
remodelled through the process of activation-resorption-formation. However, this may pose a 147 
question on the mechanisms that localized signals use to stimulate the bone remodelling foci. 148 
One of these signals may be the presence of extracellular nucleotides resulting in c-Fos 149 
signalling. Also, it has been shown that along with the local stimuli, some hormones act to 150 
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increase the rate of bone turnover activation, triggering the transcription of c-Fos, which plays an 151 
important part in bone turnover [21]. 152 
From the experiments described here, it was observed that GIP alone was a stimulus for 153 
c-Fos expression at its highest concentration. However, when ATP was present, the induction of 154 
c-Fos was much higher reaching up to 70%, over the control. This finding is relevant since GIP 155 
has been reported to exert effects on bone tissue, and this could be done through the increase of 156 
cAMP response element binding (CREB) phosphorylation [22]. An enhancement and/or synergy 157 
of this cascade can be predicted in the presence of extracellular nucleotides, suggesting that GIP 158 
systemic effects can be directed by the release of nucleotides to the bone surroundings. 159 
Therefore, multiple pathways, involving P2 and GIP receptors can coordinate a synergistic 160 
induction of gene expression in osteoblasts triggering direct responses from osteoblasts to 161 
modulate bone formation, involving c-Fos and ATP, to exert a more efficient signalling for bone 162 
remodelling. 163 
Also, it was shown that the combination of GLP-1 and ATP was capable of  provoking an 164 
increased transcription of c-Fos in osteoblastic cells, suggesting that, in states of high energy like 165 
those exhibited after feeding (GLP-1 is released after a meal and the circulating levels increase 166 
rapidly [23]), this peptide could be  involved in bone turnover helped by the presence of ATP 167 
and by triggering mechanisms that generate the transcription of c-Fos and subsequent  activation 168 
of bone remodelling in specific places. However, the lack of response at bone metabolism levels 169 
observed in some clinical trials [8], and the link of GLP-1 to bone turnover may be explained by 170 
a factor that acts in a more localized manner, like ATP. 171 
In addition, GLP-2 induced a response in the presence of ATP, prompting a c-Fos peak at 172 
30 min. Unlike GLP-1, GLP-2 has shown more responses in bone turnover in terms of 173 
decreasing bone resorption markers [9–11] and its involvement in bone turnover may be 174 
explained in terms of intracellular cascades triggered by GLP-2 itself, being modulated by ATP.  175 
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This enhancement of the induction in the presence of ATP (i.e. GIP, GLP1, and GLP-2), 176 
suggests a synergistic mechanism between nucleotides and these systemic regulators to “switch 177 
on” localized cell signals, which in turn can modulate bone-remodelling processes [24], in 178 
certain feeding/fasting states. In this regard, in terms of energy homeostasis, after a meal, the 179 
levels of these three hormones are increased, and trigger a number of systemic responses (e.g. 180 
insulin release) and intracellular cascades [22, 25]. Also, levels of ATP are related to nutrient 181 
ingestion and play a role in the appetite behaviour [26, 27]. Once ATP is present in the 182 
extracellular milieu, it functions as an autocrine/paracrine signal and binding to P2Y receptors 183 
leads to further c-Fos activation which in turn activates transcriptional and regulation factors 184 
related to cell differentiation [20]. Together, these factors are likely to be combined to prompt 185 
responses from bone cells, as there is a body of evidence of the effects of the gut hormones on 186 
bone metabolism modulation [4–11].  187 
Although a set of five hormones was evaluated, a feature of the current study is that the 188 
evaluation was carried out using two different methodologies. These data come from cell lines, 189 
and we acknowledge  that subsequent studies on  primary cell culture could provide stronger data 190 
on the role of c-Fos  when bone cells are grown in presence of gut hormones and ATP, since the 191 
osteoblastic differentiation stage may modulate P2 receptor expression and hence the observed 192 
responses [28]. There is a well established heterogeneity in expression of P2 receptors in primary 193 
cell cultures [29] and thus studies on established well-characterised cell lines are important in 194 
elucidating complex signalling pathways. Our results underscore the ability of the gut hormones 195 
to generate systemic signals in the digestive tract, and that are translate as localized signals to act 196 
on bone remodelling foci. 197 
These findings could be relevant from a point of view of clinical management of bone 198 
loss secondary to inadequate nutrient intake or changes in the feeding patterns (e.gr. gastric 199 
bypass) [30]. Currently, P2 receptor agonists are in development, which could provide new 200 
therapeutic agents for bone disease [31]. Furthermore, there are other potential strategies for 201 
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 9 
increasing ATP locally in bone, including ultrasound [32], and possibly vibration and exercise, 202 
which administered postprandially could be used to exploit the positive interaction with gut 203 
hormones to promote bone growth. 204 
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Fig. 1. c-Fos induction in transfected Saos-2 cells. (A), GIP alone (p=0.019) and combined 212 
with ATP (p<0.001) induced significant higher levels of c-Fos. B) OB treatment increased c-Fos, 213 
when 10-8M was present (p=0.011), but no significant changes were observed in the presence of 214 
ATP. PTH was used as a positive control of induction. Data were normalized to control and 215 
results are expressed as the average of fold change, n= 10, ±SEM.  216 
Fig. 2. Time course patterns exhibited by c-Fos induction.  A) Time course of c-Fos induction 217 
after LIC, D+A, D+S, PTH: a maximum peak at 60 min and depletion at 120 min were observed 218 
in LIC, D+A and D+S. PTH induced a maximum induction at 30 min and depletion at 60 min. B) 219 
A maximum peak at 60 min and depletion at 120 min were observed after GLP-1, with no 220 
significant differences compared to LIC; GLP-2 had similar increase as GLP-1 at 60 min, but no 221 
depletion was observed at 120 min, with higher levels that GLP-1 and LIC. C) GLP1 combined 222 
with ATP 10-5M induced a maximum peak at 60 min and depletion at 120 min; GLP-2 had an 223 
increase at 30 min, and depletion was observed at 60 min. Results are expressed as the average 224 
of fold change, n=6, ±SEM. Comparisons were performed against the paired time points 225 
(*p<0.001, **p<0.01, ***p<0.05 compared with their respective control, either LIC or D+A at 226 
their respective point times).  227 
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LIC=Low induction control (DMEM alone); D+A=DMEM plus ATP; D+S= DMEM plus 10% 228 
FCS (positive control); PTH= PTH 10-9 M (positive control).  229 
 230 
 231 
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